The present invention provides liquid formulations of antibodies or antibodyfragments that immunospecifically bind to an IL-9 polypeptide, whichformulations exhibit stability, low to undetectable levels of aggregation, andvery little to no loss of the biological activities of the antibodies orantibody fragments, even during long periods of storage. In particular, thepresent invention provides liquid formulations of antibodies or fragmentsthereof that immunospecifically bind to an IL-9 polypeptide, whichformulations are substantially free of surfactants, sugars, sugar alcohols,amino acids other than histidine (preferably with pKa values of less than 5and above 7), and/or other common excipients. Furthermore, the inventionprovides methods of preventing, treating or ameliorating a disease or disorderassociated with or characterized by aberrant expression and/or activity of anIL-9 polypeptide, a disease or disorder associated with or characterized byaberrant expression and/or activity of the IL-9R or one or more subunitsthereof, an autoimmune disease, an inflammatory disease, a proliferativedisease, or an infection (preferably, a respiratory infection), or one or moresymptoms thereof, utilizing the liquid formulations of the present invention.
